Usage Examples
- The ANDA carries a Paragraph IV certification, so plan for notice letters and litigation before approval.
- Their strength change was never the subject of an approved petition, so the ANDA route was closed to them.
- We mapped every RLD attribute to the ANDA before writing a line of the bioequivalence protocol.
What is Abbreviated New Drug Application (ANDA)?
Abbreviated New Drug Application (ANDA) is the FDA marketing application for a generic drug, which wins approval by demonstrating bioequivalence to a reference listed drug rather than repeating the clinical safety and efficacy trials behind an NDA.
An Abbreviated New Drug Application exists so a generic duplicate does not have to re-prove what the innovator already established. Instead of an independent safety and efficacy program, the ANDA carries evidence that the product is the same drug, delivered the same way, performing the same way in the body. FDA reviews sameness and equivalence, not a first-in-class benefit-risk case.
An ANDA covers a product that matches its reference listed drug on active ingredient, route of administration, dosage form, strength, conditions of use, and labeling, with deviations permitted only where FDA has approved a petition. An ANDA does not cover a new active moiety, a new indication, or a product leaning on its own clinical evidence; those sit outside the route and belong in an NDA.
An ANDA is built in practice as a sameness dossier plus a patent position. The regulatory team maps every reference listed drug attribute to a matching claim in the application, the bioequivalence study supplies the performance evidence, and a certification is filed against each patent submitted to FDA for that reference product. Certification wording and labeling alignment decide outcomes as often as the science does.
Not to be confused with
- NDA
- an NDA carries its own preclinical and clinical evidence to establish safety and effectiveness. An ANDA carries none of that and instead proves sameness plus bioequivalence to a product FDA has already approved.
- RLD (Reference Listed Drug)
- the RLD is the approved product an ANDA points at; the ANDA is the application pointing at it. One RLD supports many ANDAs, and the RLD's approved conditions of use define the outer limit of what any ANDA can claim.
- Orange Book
- the Orange Book is FDA's published list of approved products, therapeutic equivalence ratings, and the patent information submitted for each product. It is the input an ANDA reads to pick an RLD and build its certifications, not a type of application.
- Bioequivalence
- bioequivalence is one evidence requirement inside an ANDA, not the whole application. Passing a bioequivalence study proves nothing about whether the ingredient, dosage form, strength, or labeling actually match the RLD.
The content list at 21 CFR 314.94(a) is the checklist a reviewer works from. These are the anchors.
What you must do
- 1Refer the application to a listed drug, ordinarily the product FDA selected as the reference standard for bioequivalence testing21 CFR 314.94(a)(3)
- 2Show that route of administration, dosage form, and strength are the same as the reference listed drug, except for differences that have been the subject of an approved petition21 CFR 314.94(a)(6)
- 3Submit information showing the drug product is bioequivalent to the reference listed drug relied upon21 CFR 314.94(a)(7)
- 4File a certification for each patent, using the prescribed Paragraph I through IV wording, including the Paragraph IV statement that the patent is invalid, unenforceable, or will not be infringed21 CFR 314.94(a)(12)
- 5Establish bioequivalence using an in vivo or in vitro method appropriate to the product, since the regulation permits several21 CFR 320.24
Common mistakes
Paraphrasing the patent certification
The Paragraph I through IV language at 21 CFR 314.94(a)(12) is prescribed text, not a summary the applicant drafts. A reworded or missing certification is a defect a reviewer finds on the face of the application, and correcting it costs a filing cycle, not an amendment.
Treating a formulation change as minor
Route of administration, dosage form, and strength must match the RLD unless the difference is already the subject of an approved petition. Teams discover late in development that the change they made needed a petition first, and that the ANDA route was never open to that product.
Assuming bioequivalence means one blood-level study
21 CFR 320.24 permits several in vivo and in vitro methods, and the right one depends on the product. Defaulting to a pharmacokinetic study for a locally acting or non-systemically absorbed product generates data that does not answer the question FDA is asking.
When This Matters
- The ANDA carries a Paragraph IV certification, so plan for notice letters and litigation before approval.
- Their strength change was never the subject of an approved petition, so the ANDA route was closed to them.
- We mapped every RLD attribute to the ANDA before writing a line of the bioequivalence protocol.
Frequently Asked Questions
An ANDA is abbreviated because its required contents, listed at 21 CFR 314.94(a), substitute evidence of sameness and bioequivalence for an independent safety and efficacy program. The applicant shows the product matches an approved reference listed drug on ingredient, route, dosage form, strength, conditions of use, and labeling, then proves equivalent performance.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
